We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LYT-100

News List

PureTech Health reports increase in 2020 revenue pharmaceutical-technology
April 16, 2021
PureTech Health has reported an increase in revenue to $11.77m last year from $9.81m in 2019.
PureTech launches phase II ‘long COVID’ drug trial pharmatimes
December 08, 2020
PureTech has initiated a phase II trial of its investigational drug candidate LYT-100 in long COVID characterised by respiratory complications and related sequelae.
PureTech advances experimental COVID-19 drug into global trials pharmatimes
May 29, 2020
UK clinical-stage biotherapeutics group PureTech has unveiled plans to advance its wholly-owned clinical-stage product candidate LYT-100 (deupirfenidone) as a potential treatment for serious respiratory complications ...
First patient dosed in potential lymphoedema treatment trial pharmatimes
March 06, 2020
PureTech has announced that the first participant has been dosed in a clinical study of LYT-100, the company’s product candidate for the potential treatment of lymphoedema and other fibrotic conditions.